Join our daily newsletter At The Bell to receive exclusive market insights
- 4DMedical (4DX) releases its image processing software, CT LVAS, in Australia
- CT LVAS is reportedly similar to the XV LVAS product but utilises computed tomography (CT) imaging infrastructure instead of X-ray equipment
- 4DMedical says launching its second product in Australia is the “sensible” choice in terms of the density of CT scanners per head of population, compared to the US or other nations outside of Japan
- More importantly, it significantly broadens the accessibility of functional lung imaging for Australians living with lung disease
- Shares in 4DMedical are up 1.64 per cent, trading at 62 cents as of 1:35 pm AEDT.
Respiratory imaging technology company 4DMedical (4DX) has announced its latest addition to its product pipeline in Australia.
The Computed Tomography Lung Ventilation Analysis Software (CT LVAS) reportedly provides an almost identical report to its proven XV LVAS product but utilises computed tomography (CT) imaging infrastructure instead of X-ray equipment.
The company said launching in Australia was the “sensible” choice as it stands above the US and every other nation outside of Japan in terms of the density of CT scanners per head of population.
The CT LVAS being available also significantly broadens the accessibility of functional lung
imaging for Australians living with lung disease.
“This product extension represents rapid progress in developing a more comprehensive product pipeline,” CEO and founder Andreas Fouras said.
“CT LVAS also represents significant progress towards release of our CT:VQ technology, which will allow quantitative functional imaging of both ventilation (airflow) and perfusion (blood flow) within the lungs from a traditional CT scan.
“This advance will obviate the need for either CT contrast or nuclear imaging radiotracers, representing a material step forward for medical imaging and offering 4DMedical access to significant pricing premiums over XV LVAS and CT LVAS.”
The software will position the company to leverage I-MED’s extensive existing CT network to provide greater patient access.
In line with 4DMedical’s commercialisation strategy, the I-MED agreement represents a significant opportunity to drive revenue for the company, as it creates a framework for the rapid commercialisation of the software in Australia.
Shares in 4DMedical were up 1.64 per cent, trading at 62 cents as of 1:35 pm AEDT.
